Perimenopausal Depression

The short version

●The perimenopause — the years of hormonal fluctuation leading up to the final menstrual period — is a window of increased risk for depression, including in women with no prior history.
●It is driven by fluctuating (not just declining) estrogen interacting with sleep disruption, vasomotor symptoms (hot flashes/night sweats), life stressors, and prior mood history.
●Perimenopausal depression is real depression — not "just hormones" or "just stress" — and meets the same criteria, but the menopausal context shapes treatment.
●First-line treatment is antidepressants (SSRIs/SNRIs) and/or psychotherapy; for some women, estrogen therapy has antidepressant benefit during perimenopause specifically and can also treat co-occurring vasomotor symptoms.
●Treating sleep and hot flashes often substantially improves mood, since they are tightly linked.
●Ketamine is not first-line; it is for treatment-resistant perimenopausal depression after adequate standard care, as with depression in any other context.

Clinical definition

Perimenopausal depression refers to a major depressive episode, or clinically significant depressive symptoms, arising during the perimenopause — the transition, often spanning several years in the 40s to early 50s, marked by erratic fluctuations in estrogen and progesterone before menstruation ceases. Epidemiologic and longitudinal studies show the perimenopause is a window of elevated depression risk, including first-onset depression in women without prior episodes, with risk concentrated in the late transition and early postmenopause. The drivers are multifactorial: it is the variability of estrogen (which modulates serotonin and other mood systems) more than its absolute level, compounded by vasomotor symptoms, fragmented sleep, and the psychosocial stressors common at midlife, with prior depression and severe vasomotor symptoms as key risk factors. Clinically it is genuine depression meeting standard criteria — the perimenopausal context informs treatment rather than changing the diagnosis. Dedicated expert guidelines (Maki 2018) outline how to evaluate and treat it.

How it differs from related conditions

vs. Major depressive disorder

Perimenopausal depression is MDD occurring in a specific hormonal window; the difference is contextual (timing, hormonal and vasomotor contributors) and informs treatment options like hormone therapy.

vs. Normal menopause transition symptoms

Hot flashes, sleep changes, and irritability are common in perimenopause without meeting depression criteria; depression is diagnosed when the full syndrome and impairment are present.

vs. Premenstrual dysphoric disorder

Both are reproductive-hormone-linked mood conditions, but PMDD is cyclic with the menstrual cycle, whereas perimenopausal depression tracks the longer transition.

vs. Hypothyroidism / medical causes

Midlife fatigue and low mood can reflect thyroid disease or other medical causes, which should be screened.

First-line treatments

Antidepressants (SSRIs/SNRIs)

First-line, as for depression generally; some SNRIs/SSRIs also reduce hot flashes, addressing two problems at once.

Psychotherapy (CBT, IPT)

Effective alone for milder depression and in combination; IPT is well-suited to the midlife role transitions involved.

Hormone therapy (estrogen)

Has antidepressant benefit during perimenopause specifically for some women (especially with vasomotor symptoms), per expert guidelines — a distinctive option in this window, decided individually with attention to risks.

Treating sleep and vasomotor symptoms

Improving hot flashes and sleep often markedly improves mood given how tightly linked they are.

When standard treatments fail

When first-line antidepressants and/or psychotherapy (with or without hormone therapy) do not adequately treat perimenopausal depression, the steps mirror treatment-resistant depression generally — confirm adequate trials, optimize or switch agents, combine medication with therapy, and address contributors (sleep, vasomotor symptoms, thyroid). For the genuinely treatment-resistant, rapid-acting options including ketamine become reasonable, exactly as they would for treatment-resistant depression in any other context.

Where ketamine fits

Ketamine in perimenopausal depression is not different in principle from ketamine in major depression generally: it is not first-line, and it is for the treatment-resistant subgroup after adequate standard care. What is distinctive about the perimenopausal window is that there are additional first-line levers to try first — antidepressants, psychotherapy, and, for some women, estrogen therapy that can treat both mood and vasomotor symptoms — plus the high yield of fixing sleep and hot flashes. Once those have been adequately addressed without sufficient response, ketamine's rapid antidepressant effect is a reasonable option for the resulting treatment-resistant depression. Tovani treats it as it would any treatment-resistant depression, while ensuring the perimenopause-specific options have been considered.

Where this fits with Tovani

Tovani treats perimenopausal depression that has proven treatment-resistant after adequate first-line care. Because this window has distinctive levers, eligibility screening captures menopausal status, vasomotor symptoms, sleep, prior treatments, and whether hormone therapy and standard antidepressant/psychotherapy options have been tried. Patients early in the workup are encouraged to pursue those first (often with their gynecologist or primary care), with ketamine reserved for genuine treatment resistance.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Is it depression or just menopause?

It can be both, and they interact. Hot flashes, sleep disruption, and mood swings are common in perimenopause without being depression — but the transition is also a window of genuinely elevated depression risk. When low mood, loss of interest, and the full symptom picture persist and impair you, it's depression and deserves treatment, whatever the hormonal context.

Can hormone therapy treat my depression?

For some women during perimenopause specifically, estrogen therapy has an antidepressant benefit and can also treat hot flashes — a distinctive option in this window noted in expert guidelines. It's decided individually with attention to risks, and it doesn't replace antidepressants or therapy for everyone.

Why does fixing my sleep and hot flashes help my mood?

Because they're tightly linked. Night sweats fragment sleep, and poor sleep worsens mood, creating a loop. Treating vasomotor symptoms and sleep often improves depression substantially, which is why it's a high-yield part of care.

Where does ketamine fit?

The same place it does for depression generally: not first-line, but a reasonable option for treatment-resistant perimenopausal depression after antidepressants, therapy, and (where appropriate) hormone therapy and sleep/hot-flash treatment haven't worked.

References

Maki PM et al. 2018, Menopause — Expert guidelines for the evaluation and treatment of perimenopausal depression, including the roles of antidepressants, psychotherapy, and hormone therapy. (PMID 30179986)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression, the basis for ketamine's role once perimenopausal depression proves treatment-resistant. (PMID 23982301)
Sanacora G et al. 2017, JAMA Psychiatry — APA consensus on ketamine for mood disorders. (PMID 28249076)

Last reviewed by Dr. Ben Soffer, DO on May 31, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.